Physician profile

Lloyd Damon

Medical Oncology · San Francisco, CA

NPI 1548224058

$774.87

in general payments reported to CMS, 2019-2025

15 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$317.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alexion Pharmaceuticals, INC. $300.00 2019-2021
Actelion Pharmaceuticals US, INC. $225.21 2019-2024
Kamada Ltd. $146.75 2024
Abbvie INC. $45.26 2024
Pharmacyclics LLC, An Abbvie Company $26.97 2021
Stemline Therapeutics INC. $16.75 2019
Acrotech Biopharma INC. $13.93 2021

8 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lloyd Damon

$774.87

in general payments reported 2019-2025

Years
2019-2024
Top company
Alexion Pharmaceuticals, INC.

https://glasscript.com/doctor/577900/lloyd-damon

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.